Stevanato Group announced today that it expanded the capacity of its Vertiva on-body device for subcutaneous large-volume drug delivery. The Italy-based company says its Vertiva platform now covers 10mL volumes. It plans to present the latest Vertiva development at CPhI Milan next month. Vertiva features a single-use injection unit (or pod) and a multi-use smart […]
Stevanato Group
Stevanato Group brings former CEO back to corner office
Stevanato Group (NYSE:STVN) announced today that its board of directors appointed Franco Stevanato as its new CEO. Stevanato, currently a board director and the company’s executive chair, succeeds Franco Moro in the corner office. Moro’s employment agreement continues through June 30, 2024, after which he will remain on the company’s board. This marks Stevanato’s second […]
8 drug delivery innovations you should know
Innovations in drug delivery never stop, and over the past 12 months or so a wide variety have been in the spotlight. Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing the many ways we can […]
Stevanato Group unveils on-body drug delivery device
Stevanato Group (NYSE:STVN) today unveiled Vertiva, the latest release of its patented on-body drug delivery system. Piombino Dese, Italy-based Stevanato Group designed Vertiva with the ability to switch between basal and bolus injections. It has suitability for a wide range of subcutaneous therapies. In March, Stevanato Group announced plans to bring this on-body device to […]
Stevanato Group, Thermo Fisher to bring on-body drug delivery system to market
Stevanato Group (NYSE:STVN) today announced a collaboration with Thermo Fisher Scientific (NYSE:TMO) on drug delivery technology. The partnership aims to bring a fully integrated, on-body delivery system platform for subcutaneous administration to market. Stevanato Group said in a news release that the planned device will be semi-reusable and provide micro-precision basal doses and full-content bolus […]
Stevanato Group, Recipharm partner on pre-filled syringes for inhaled therapeutics
Stevanato Group (NYSE:STVN) today announced a collaboration with Recipharm to manufacture pre-fillable syringes for soft mist inhalers. Piombino Dese, Italy-based Stevanato Group plans to lend manufacturing experience to support production of the syringes. As part of the collaboration, it intends to provide and manufacture its Alba glass pre-fillable syringe. Stevanato Group will assemble Alba with […]
Stevanato Group, Owen Mumford to collaborate on Aidaptus auto-injector
Stevanato Group (NYSE:STVN) announced today that it signed an exclusive agreement with Owen Mumford for its auto-injector technology. Piombino Dese, Italy-based Stevanato Group’s agreement makes it an exclusive manufacturing partner for Owen Mumford’s Aidaptus auto-injector. Under the agreement, Stevanato Group will mold the components for the technology and provide final and sub-assembly equipment, along with […]
Stevanato Group, Bexson expand partnership for wearable drug delivery device
Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration. Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and […]
Stevanato Group acquires facility set to become manufacturing hub in China
Stevanato Group (NYSE:STVN) announced today that it acquired a facility in Zhangjiagang, China, for a new manufacturing plant. Piombino Dese, Italy-based Stevanato Group expects to begin renovations on the facility in the spring of 2022 as it works to expand in China with a new manufacturing hub for drug containment, drug delivery and diagnostic development. […]
Stevanato Group extends licensing agreement with Haselmeier for pen injector tech
Stevanato Group (NYSE:STVN) announced today that it signed an extension to a licensing agreement with Haselmeier over its pen injector technology. Piombino Dese, Italy-based Stevanato Group’s license extension gives the company exclusivity to offer the Axis-D pen injector technology in support of a broader range of drugs for its biopharma customers beyond diabetes, including areas […]
